Frequently Asked Questions

PBM audits often reveal inventory discrepancies, or “shortfalls,” that may lead to broader investigations and significant legal consequences. Providers should understand how to resolve these allegations and limit liability arising from inventory management errors.

Common Sources of Inventory Discrepancies

First, it is important to note that the vast majority of inventory discrepancies arise from inadvertence or human error. Many pharmacists fail to timely update their pharmacy management software when NDCs change, particularly generics, because the focus is on dispensing the correct drug. Nonetheless, the PBMs do not accept that AWP may be the same across all products, and thus immaterial.

In addition, automatic refill prompts may cause prescriptions to be placed in the "will call" bin for medications that patients may not need, particularly if their underlying medical condition involves variable levels of adherence, such as for diabetics and patients with lung or bronchial disorders.

Other common mistakes involve the dispensing of generics in place of brand, particularly where the same manufacturer markets both a generic and branded version of the drug in virtually identical packaging, i.e., certain insulins. Similarly, discrepancies may result from employee misconduct and theft.

Finally, billing discrepancies may or may not result from inventory discrepancies, but our focus for purposes of this discussion is the billing of medication that was never dispensed or ordered.

Inventory Shortfalls Involving Controlled Substances

Second, different requirements apply with respect to shortages of controlled substances, which will be closely scrutinized given the regulatory climate. DEA regulations require the filing of a Form 106 that discloses the theft or significant loss of controlled substances within one business day of discovery.

In addition to PBM audits, DEA Diversion Investigators are required by annual work plans to conduct regulator inspections/audits of DEA registrants, and any unexplained inventory discrepancies likely will referred for further investigation by law enforcement. Due to intense scrutiny around the opioid epidemic, these referrals are more likely to be pursued.

Potential Solutions to Identified Inventory Shortfalls

Third, following a PBM audit or DEA inspection that uncovers inventory shortfalls, there are a number of possible outcomes. Providers may need to fight network suspension or termination; administrative and licensing proceedings; civil lawsuits; and potential criminal charges.

At this stage, the focus should be on limiting liability and the more severe potential consequences through a well-organized and strategic defense strategy. Consideration should be given to whether the inventory discrepancy can credibly be described as an operational issue, or whether other factors, such as referral relationships, lack of medical necessity, and high-reimbursing products, will require some attention and explanation.  

Finally, mistakes are just that, and we all make them. Inventory discrepancies are serious challenges, but they can be resolved satisfactorily, with no or limited consequences to your business or livelihood. Here at HLA, we rely on our attorneys' experience as former top-level McKesson executives and prosecutors to approach these cases with more insight and knowledge than the other side. This equation is our formula for success because it allows us to explain to the other side the ways in which their analysis is flawed, leading to resolution. Please do not hesitate to contact us for a free consultation to learn more about our approach.

MORE ARTICLES BY CATEGORY

Get a Free Case REVIEW

100% Confidential & Secure. Your details are safe with us.

We'll speak soon!

In the meantime, why not find out more about us or visit our blog.

Alternatively, give us a call at (800) 345 - 4125

Oops! Something went wrong while submitting the form.

How DME Suppliers Can Maintain Compliance with Medicare Enrollment Requirements

If you are a Durable Medical Equipment (DME) supplier and you are fearful of being scrutinized by CMS or the National Provider Enrollment contractors for violating the onerous Medicare enrollment standards, we hope this article will help. It lays out the essential steps to maintain compliance with Medicare's enrollment requirements. We break down the complex regulations surrounding Medicare enrollment standards, covering everything from initial enrollment and accreditation to revalidation and reporting changes, and tells providers to reach out to Health Law Alliance if they are seeking advice.

Read More >>

OIG Issues Advisory Opinion 25-03, A Roadmap for Compliant Telehealth Staffing Models

On June 6, 2025, the US Department of Health and Human Services’ Office of the Inspector General issued Advisory Opinion 25-03, offering key compliance guidance for telehealth arrangements involving the leasing of health care providers and other administrative services to a physician-owned professional corporation (PC). Learn more about the opinion and what it tells us about the future of telehealth regulatory compliance.

Read More >>

HLA Wins Full Reversal of PBM Audit Findings for Maryland Pharmacy

Health Law Alliance achieved full reversal of final audit findings for a Maryland pharmacy—just one of numerous victories our attorneys has achieved for our clients. Learn more about the stunning reversal and how Health Law Alliance’s tenacious advocacy can help your pharmacy in PBM disputes.

Read More >>

HLA Attorney Anthony Mahajan Secures Major Victory Over Cardinal as Federal Court Dismisses Lawsuit Against Independent Pharmacies

Health Law Alliance secured a major win for independent pharmacies with the dismissal of Cardinal Health’s lawsuit, exposing it as a baseless attempt to intimidate smaller providers. This outcome reinforces the firm’s commitment to protecting healthcare businesses from corporate overreach.

Read More >>